Business Wire

HCHF

15.5.2020 20:50:06 CEST | Business Wire | Press release

Share
Millions Across the Globe Unite in Prayer for End of Coronavirus Pandemic in Response to HCHF Call

The world has witnessed what is described as an unprecedented historic scene on Thursday, 14th May, when millions of people around the world united in prayer to supplicate to God for an end to the COVID-19 pandemic and to help scientists and researchers find a vaccine against the disease as quickly as possible.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200515005533/en/

This came in response to the Higher Committee of Human Fraternity (HCHF) humanitarian call, which was blessed and supported by His Eminence Dr. Ahmed El-Tayeb, Grand Imam of Al Azhar, and His Holiness Pope Francis, Head of the Catholic Church, and received the support of a number of kings, presidents, leaders, and leading political, religious, and media figures from all over the world.

The HCHF’s call to pray for humanity, which was announced in a statement issued in 14 languages, gained momentum on social media platforms, as the initiative recorded 36 billion cumulative digital media interactions, engagement and potential reach as estimated by Talkwalker analytics report, since it was launched on 2nd May till 15th May. The initiative’s official website (pray.forhumanfraternity.org) and social media accounts have hosted a 24-hour livestream for the global prayers.

#PrayForHumanity hashtag trended on social media in many countries, including France, Germany, India, KSA, UAE, Spain, Egypt, and Italy, reflecting the great success of the initiative which also attracted the attention of global media.

The HCHF extended thanks to all leaders, religious, political, and popular institutions, and all those who participated in the global prayer day.

Judge Mohamed Abdel Salam, HCHF Secretary-General, praised the unexpected successes of the initiative, stressing that such successes will contribute to achieving a true global unity.

He said: “The voices of supplications to God that were made in an unprecedented humanitarian scene in all continents of the world to end this pandemic are reasons for us to feel optimistic and give us confidence that our unity will help the world overcome this crisis.”

Monsignor Yoannis Lahzi Gaid, Personal Secretary to His Holiness Pope Francis, stated that the participation of different religions and beliefs in this initiative also the global response paves a way forward to continue working for humanity, especially in facing this pandemic. He said: “We will keep supplicating to God and work with our brothers from different religions and beliefs to transform this suffering to an opportunity for more solidarity and fraternity.”

The HCHF is an independent international committee that includes a group of experts and leaders in inter-culture communication and interfaith dialogue. It aims to achieve the higher goals for human fraternity signed by His Eminence Dr. Ahmed El-Tayeb, Grand Imam of Al Azhar, and His Holiness Pope Francis, Head of the Catholic Church, in Abu Dhabi in February 2019, under the patronage of HH Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi, the patron of the Document on Human Fraternity.

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye